SCHEMBL4155387

SCHEMBL4155387

NC(=O)c1ccc(Oc2cccc(Br)c2)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ICAM1 P05362 3/20 0.54
SELE P16581 3/20 0.54
PARP1 P09874 1/20 0.44
PARP15 Q460N3 2/20 0.39
PARP14 Q460N5 2/20 0.39
PARP10 Q53GL7 2/20 0.39
TNKS O95271 1/20 0.39
TNKS2 Q9H2K2 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
F2 P00734 2/20 0.39
KMT2A Q03164 2/20 0.38
CYP1A2 P05177 3/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CDC7 O00311 2/20 0.38
DYRK3 O43781 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4161369 0.84 CYP3A4 (0.42) ICAM1SELEPARP1PARP15PARP14
SCHEMBL4148474 0.82 CDK1 (0.54) ICAM1SELEPARP1PARP15PARP14
SCHEMBL4156126 0.82 ICAM1 (0.54) ICAM1SELEPARP1PARP15PARP14
SCHEMBL4144009 0.81 PARP10 (0.50) ICAM1SELEPARP1PARP15PARP14
SCHEMBL4154998 0.79 PRSS1 (0.43) ICAM1SELEPARP15PARP14PARP10
SCHEMBL4150602 0.76 SPHK2 (0.51) PARP10KMT2AALDH1A1SMN1; SMN2KDM4E
SCHEMBL1680519 0.73 MAOB (0.39) ICAM1SELEKMT2ACYP1A2CYP2C9
SCHEMBL4155072 0.72 ICAM1 (0.49) ICAM1SELEPARP15PARP14PARP10
SCHEMBL4159295 0.72 IKBKB (0.54) ICAM1SELEPARP15PARP14PARP10
SCHEMBL28541614 0.71 EPHX2 (0.58) PARP1KMT2AALDH1A1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD ICAM1 4352/4885SELE 3545/4885PARP1 992/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 ICAM1 4405/4885SELE 4499/4885PARP1 3078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.